At the AUA 2024 Annual Meeting, Katie S. Murray, DO, of NYU Langone Urology and Bellevue Hospital, and Stephan Broenimann, MD, of Johns Hopkins University, highlight an evaluation of urinary comprehensive genomic profiling for non-invasive detection and molecular staging in a cohort of patients undergoing treatment for UTUC. This research, Dr. Broenimann suggests, provides evidence that urinary comprehensive genomic profiling can provide valuable diagnostic and prognostic information for the evaluation for UTUC. ...
Urothelial Carcinoma Diagnostics
Advertisement
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Liquid biopsy can benefit patients with UTUC by detecting rare events at higher incidences compared to tissue-based samples.
Researchers investigated the ability of variant histology to predict oncological outcomes.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Advertisement
Video Insights
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
